A unique three-way Philadelphia chromosome variant t(4;9;22)(q21;q34;q11.2) in a newly diagnosed patient with chronic phase chronic myeloid leukemia: a case report and review of the literature
Autor: | Masakazu Yamamoto, Kana Nanjo, Ryo Sato, John M. Magenau, Keiko Aizawa, Masashi Hosokawa, Tomomi Toubai, Yuka Torii, Akane Yamada, Kenichi Ishizawa, Ryan A. Wilcox, Masahito Himuro, Satoshi Ito |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male 0301 basic medicine Fusion Proteins bcr-abl Case Report Chromosomal translocation Philadelphia chromosome Translocation Genetic Three-way variant 03 medical and health sciences 0302 clinical medicine Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases t(4 22)(q21 Q34 Q11.2) medicine Humans CML ABL business.industry breakpoint cluster region Myeloid leukemia Karyotype General Medicine medicine.disease Dasatinib 030104 developmental biology Karyotyping 030220 oncology & carcinogenesis Cancer research Medicine business Bosutinib medicine.drug |
Zdroj: | Journal of Medical Case Reports, Vol 15, Iss 1, Pp 1-6 (2021) Journal of Medical Case Reports |
ISSN: | 1752-1947 |
DOI: | 10.1186/s13256-021-02885-4 |
Popis: | Background Chronic myeloid leukemia is a hematologic malignancy associated with the fusion of two genes: BCR and ABL1. This fusion results from a translocation between chromosomes 9 and 22, which is called the Philadelphia chromosome. Although the Philadelphia chromosome is present in more than 90% of patients with chronic myeloid leukemia, 5–8% of patients with chronic myeloid leukemia show complex variant translocations. Herein, we report a unique case of a three-way translocation variant in chronic phase chronic myeloid leukemia. Case presentation A 40-year-old Asian male who presented with leukocytosis was diagnosed with chronic phase chronic myeloid leukemia. Cytogenetic karyotyping analysis showed 46,XY,t(4;9;22)(q21;q34;q11.2). He was treated with bosutinib and then changed to dasatinib because of intolerance, and MR4.5 (BCR-ABL/ABL ≦ 0.0032%, international scale) was achieved after 17 months of continuous treatment. Conclusion This was the 14th case of t(4;9;22), in particular, a new variant Ph translocation involved in chromosome 4q21 and the first successful case treated with tyrosine kinase inhibitors in the world. We summarize previous case reports regarding three-way variant chromosome translocation, t(4;9;22) and discuss how this rare translocation is linked to prognosis. |
Databáze: | OpenAIRE |
Externí odkaz: |